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Inflammation may play a role in increased risk of heart fail-
ure (HF) that is associated with obesity, metabolic syn-
drome (MS), and diabetes. This study investigated
associations between inflammatory markers, MS, and inci-
dent HF in a population with a high prevalence of diabetes,
obesity, and MS. The cohort consisted of 3098 American
Indians without prevalent cardiovascular disease who had
C-reactive protein (CRP) and fibrinogen measured at the
Strong Heart Study phase II examination. Independent
associations between inflammatory markers, MS, and HF
were analyzed by Cox hazard models. During a mean fol-
low-up of 11 years, 218 participants developed HF. After
the adjustment for cardiovascular risk factors, fibrinogen,
(hazard ratio [HR], 1.36; 95% confidence interval [CI], 1.15–
1.59) but not CRP (HR, 1.25; 95% CI, 0.97–1.32) remained
a significant HF predictor. In individuals without diabetes,
concomitant presence of MS and elevated CRP or fibrino-
gen increased HF risk (for MS and CRP: HR, 2.02; 95% CI,
0.95–4.31; for CRP and fibrinogen: HR, 1.75; 95% CI, 0.83–
3.72). In a population with a high prevalence of obesity,
MS, and diabetes, elevated CRP and fibrinogen increased
HF risk. These associations are attenuated by the adjust-
ments for conventional risk factors suggesting that inflam-
mation acts in concert with metabolic and clinical risk
factors in increasing HF risk. J Clin Hypertens (Greenwich).
2012;14:13–19. 2011 Wiley Periodicals, Inc.
Heart failure (HF) is one of the leading causes of car-
diovascular morbidity and mortality and is related, in
most patients, to underlying coronary artery disease,
hypertension, and diabetes. In patients with HF,
regardless of etiology, elevated plasma concentrations
of inflammatory markers are associated with worsen-
ing functional class and adverse outcomes.1,2 The bio-
logical processes involved in the pathogenesis of left
ventricular (LV) dysfunction are complex and only
partially understood, but the data suggest that chronic
inflammation may play a role in promoting cardiac
fibrosis, inflammation, and cardiac remodeling.3–5
The proinflammatory state is a common characteris-
tic of clinical syndromes, such as obesity, metabolic
syndrome (MS), and diabetes, that have been associ-
ated with LV dysfunction and increased risk of HF.6–9
Reports of increasing obesity, MS, and diabetes in the
US population suggest the increased importance of
these conditions in HF risk10 and a need for better
understanding of the mechanisms involved in the pro-
gression of these conditions to overt HF.
Our group has previously reported that fibrinogen,
reflecting both inflammation and thrombosis, is a
strong correlate of preclinical cardiovascular dis-
ease.11,12 A community-based investigation has shown
an association between elevated myeloperoxidase
(MPO) levels, a leukocyte-derived enzyme, and risk of
incident HF, particularly in individuals without signifi-
cant cardiovascular risk factors,13 suggesting an inde-
pendent role of MPO in cardiac remodeling.
The Strong Heart Study (SHS) is a longitudinal
observational study, spanning more than 2 decades,
designed to characterize the metabolic and cardiovas-
cular health profile of American Indians. The SHS
cohort, with its high prevalence of obesity and diabe-
tes and elevated inflammatory markers, is an ideal
population in which to investigate the link between
metabolic risk factors, markers of inflammation, and
HF.14 The aim of this study was to determine associa-
tions between inflammatory markers, MS, and risk of
HF in a population with a high prevalence of diabetes,
obesity, and MS.
METHODS
Study Population
The SHS is a population-based cohort study of cardio-
vascular risk factors and disease in American Indians
from Arizona, North and South Dakota, and Okla-
homa who were first examined in 1989 to 2002 and
remain under surveillance for cardiovascular disease
(CVD).14 CRP, fibrinogen, and urinary albumin were
measured during SHS phase 2 (SHS2), which was
conducted between 1993 and 1995, and included
3638 men and women (aged 49–78 years) who were
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considered for the present analysis. All participants
provided informed consent.
Individuals were excluded from the current analyses
if they had prevalent CVD, including myocardial
infarction (MI), coronary heart disease (diagnosed by
electrocardiography, coronary angiography, a combi-
nation of typical symptoms and a positive stress test,
or need for a revascularization procedure), stroke, or
history of HF. Prevalent and incident cardiovascular
events were confirmed by the SHS Mortality and Mor-
bidity Committee using specified criteria for causes of
fatal and nonfatal cardiovascular events.14
To avoid the confounding link between severe
chronic kidney disease and HF, we excluded all partic-
ipants with serum creatinine >2.5 mg ⁄dL or estimated
glomerular filtration rate (eGFR) <30 mL ⁄min ⁄
1.73 m2. Thus, the cohort for the present analysis
comprised 3098 members of the SHS2 population
without prevalent cardiovascular or severe chronic
kidney disease.
In contrast to other inflammatory markers, MPO
was not measured at the phase 2 examination. To
explore the potential association of MPO with inci-
dent HF in this cohort, we measured and compared
MPO levels in 83 incident HF cases and 83 age-, sex-,
and center-matched (AZ, ND ⁄SD, and OK) controls
with available stored serum specimens.
Definitions
HF was defined as having 2 major or 1 major and 2
minor Framingham criteria concurrently in the absence
of a condition, such as end-stage renal failure leading
to massive fluid overload. Major criteria were paroxys-
mal nocturnal dyspnea or orthopnea, neck vein disten-
tion, rales, cardiomegaly, acute pulmonary edema, S3
gallop, venous pressure >16 cm water, and hepatoju-
gular reflux. Minor criteria were ankle edema, night
cough, dyspnea upon exertion, hepatomegaly, pleural
effusion, vital capacity <2 or 3 of predicted, or heart
rate >120 beats per minute. Weight loss >4.5 kg
within 5 days in response to treatment could serve as
a major or minor criterion.
MS (diagnosed at baseline [phase II] examination)
was defined via Adult Treatment Panel III (ATP III)
criteria.15 Individuals with 3 of the following criteria
were considered as having MS: waist circumference
>102 cm in men and >88 cm in women, triglycerides
>150 mg ⁄dL, high-density lipoprotein cholesterol
(HDL-C) <40 mg ⁄dL in men and <50 mg ⁄dL in
women, blood pressure >130 ⁄85 mm Hg or use of
antihypertensive drugs, and fasting glucose
>100 mg ⁄dL to <126 mg ⁄dL. A total of 930 patients
met the criteria for MS. Individuals with fasting glu-
cose >126 mg ⁄dL or using antidiabetes medications
were classified as diabetic (n=1414) and were excluded
from the MS group. Albuminuria was defined as uri-
nary albumin-creatinine ratio >30 mg ⁄g. Obesity was
defined as body mass index (BMI) >30, which classi-
fied 1669 participants as obese.
Laboratory Assays
Urinary albumin, fasting glucose, and lipid profile were
measured by standardmethods. CRP and fibrinogenwere
measured by validated methods.11,16–18 A commercially
available, CardioMPO Test (PrognostiX Inc, Cleveland,
OH)was used to determineMPO concentration.
Statistical analysis
Data are presented as mean  standard deviation for
continuous variables and as percentages for categoric
variables. Median and interquartile ranges also are
presented for continuous variables that were not nor-
mally distributed. Chi-square and Student t tests were
used to examine differences in proportions and means
of categoric and continuous variables, respectively,
between those with and without incident HF.
Wilcoxon rank-sum tests were used for continuous
variables not normally distributed.
Person-years were calculated from the date of the
baseline (phase 2) examination to the date of incident
HF, date of death if the participant died, or December
31, 2007. The distributions of fibrinogen and CRP
were divided into quartiles. Participants whose values
were in the fourth quartile were considered positive
for that inflammatory marker.
Cox proportional hazard models were used to ana-
lyze independent associations of inflammatory mark-
ers, including CRP and fibrinogen, with incident HF.
The initial multivariate model was adjusted for age
and sex. Subsequent models were further adjusted for
BMI, hypertension, low-density lipoprotein cholesterol
(LDL-C), diabetes, current smoking, and eGFR. The
results of these models are reported as hazard ratios
(HRs) and 95% confidence intervals (CIs). Conditional
logistic regression was performed to assess the associa-
tion between incident HF and MPO concentration.
Results of these models are reported as odds ratios
(ORs) and 95% CIs.
Cox proportional hazard models were used to ana-
lyze the association of MS with incident HF, among
those without diabetes. HRs and 95% CIs were esti-
mated with the use of 4 models as follows: model 1
was univariate, model 2 was adjusted for CRP, model
3 was adjusted for fibrinogen, and model 4 was
adjusted for conventional risk factors including age,
sex, LDL-C, current smoking, and eGFR. HRs and
95% CIs for incident HF were estimated by the com-
bined categories of presence or absence of MS and ele-
vated inflammatory markers, defined as CRP and
fibrinogen >75th percentile.
Cox proportional hazard models were also used to
analyze the associations of diabetes, inflammation and
HF. In the analysis of diabetes without albuminuria,
participants with albuminuria were excluded. HRs and
95% CIs for incident HF were estimated by the com-
bined categories of presence or absence of diabetes
(with or without albuminuria) and elevated inflamma-
tory markers, defined as CRP and fibrinogen >75th
percentile.
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Cumulative hazard curves of incident HF were pro-
duced among participants categorized by elevated
inflammatory markers. A log-rank test was calculated
to examine differences between the 4 groups defined
by elevation vs normality of the 2 inflammatory mark-
ers. Two-tailed P values <.05 were considered statisti-
cally significant. Data were analyzed using SAS version
9.1 (SAS Institute, Cary, NC). All graphics were cre-
ated using R software, version 2 (Free Software Foun-
dation, Boston, MA).
RESULTS
Of 3098 SHS2 participants free of CVD at baseline,
218 developed HF during a mean 11-year follow up
(incidence, 6.4 per 1000 person-years). Incident MI
occurred in 255 patients (incidence rate, 7.6 per 1000
person-years). At baseline, diabetes, obesity, hyperten-
sion, and albuminuria were more prevalent among
participants with incident HF compared with those
who remained HF-free. Individuals who developed HF
also had lower HDL-C and higher CRP and fibrinogen
levels, while total cholesterol and LDL-C were similar
between the groups (Table I).
Both markers of systemic inflammation, CRP and
fibrinogen, were significant predictors of incident HF in
analyses that were adjusted for age and sex (Table II).
Fibrinogen, but not CRP, remained a statistically signifi-
cant HF predictor after additional adjustment for con-
ventional CV risk factors, including diabetes, BMI,
hypertension, smoking, LDL-C, and eGFR (Table II). In
a limited sample of cases and controls, elevated serum
MPO was not associated with incident HF in univariate
or multivariate analyses (Table II).
To investigate associations among inflammation,
risk factors, and HF, we used Cox proportional mod-
els to examine HF risk in individuals with MS alone
(Table III), as well as with elevated inflammatory
markers (Table IV). Participants with diabetes were
excluded from this analysis. MS was present in 930 of
1684 patients (55%). Individuals with MS had no sig-
nificantly increased risk of developing HF compared
with participants without MS (HR, 1.05; 95% CI,
0.64–1.74). Adjustments for CRP, fibrinogen, and con-
ventional risk factors did not significantly affect this
relationship (Table III). Among this group, individuals
with elevated triglycerides (TGs >150 mg ⁄dL) or with
increased waist circumference (WC >102 cm in men
or WC >88 cm in women) did not have an increased
risk of incident HF (adjusted HR, 0.89; 95% CI,
0.50–1.59 for elevated TG, and HR, 1.10; 95% CI,
TABLE I. Baseline Characteristics of Study Participants With or Without Incident Heart Failure (N=3098)
Participants
With Incident HF
(n=218)
Participants Without
Incident HF
(n=2880) P Value
Age, y 61.37.7 59.47.8 .001
Women, % 72.0 62.4 .004
Body mass index, kg ⁄m2 32.47.2 31.26.4 .017
Waist circumference, cm 109.715.4 106.414.8 .001
Obesity (BMI 30), % 61.9 53.5 .016
Diabetes, % 71.8 44.1 <.001
Metabolic syndrome, No. (%)a (excluding DM) 37 ⁄ 63 (58.7) 893 ⁄ 1621 (55.1) .568
Hypertension, % 57.8 41.4 <.001
SBP, mm Hg 13421 12819 .001
DBP, mm Hg 7511 7510 .697
Total cholesterol, mg ⁄ dL 19241 19039 .503
LDL, mg ⁄ dL 12036 11833 .583
HDL, mg ⁄ dL 3911 4214 <.001
Triglycerides, mg ⁄ dL 145 (100–204) 129 (91–183) <.001b
Current cigarette smoking, % 31.3 31.8 .872
eGFR, mL ⁄min ⁄ 1.73 m2 8127 8736 .006
UACr, mg ⁄ g 46 (10–313) 12 (6–45) <.001b
Fibrinogen, mg ⁄ dL 377 (337–436) 347 (306–396) <.001b
CRP, mg ⁄ dL 4.7 (2.4–8.4) 3.7 (2.0–6.8) .004b
MPO, pmol ⁄ L (83 cases + 83 controls) 699 (436–1023) 678 (466–922) .848c
Incident MI, % 19.3 7.4 <.001
Abbreviations: CRP, C-reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; LDL,
low-density lipoprotein; MI, myocardial infarction; MPO, myeloperoxidase; SBP, systolic blood pressure; UACr, urinary albumin to creatinine ratio.
Data are presented as mean  standard deviation, percentages, or median (interquartile range [IQR]). Chi-square tests were used for differences in
proportions and Student t tests for differences in means. aMetabolic syndrome criteria included presence 3 of 5 criteria (increased waist circumfer-
ence, elevated triglycerides, low high-density lipoprotein (HDL), hypertension, and fasting glucose >100 (see Methods for details). Diabetics were
excluded from metabolic syndrome definition. bWilcoxon rank-sum test was used if distributions were not normal and median and IQR were
reported. cWilcoxon signed-rank test was used for the matched paired samples.
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0.58–2.09 for increased WC; adjusted for age, sex,
smoking, LDL cholesterol and eGFR).
We compared risk of incident HF in individuals
with MS and normal inflammatory markers with risk
associated with MS and elevated inflammatory mark-
ers. Table IV shows borderline increased incident HF
risk in individuals with MS and CRP or fibrinogen
>75th percentile (HR, 2.0; 95% CI, 0.95–4.31 and
HR, 1.8; 95% CI, 0.83–3.72, respectively).
To investigate associations among inflammation,
HF, diabetes, and albuminuria, we compared hazard
ratios for incident HF in diabetic patients without
albuminuria and diabetics with albuminuria, alone
and in the presence of elevated inflammatory markers.
In diabetics without albuminuria, concomitant pres-
ence of elevated inflammatory markers further
increased the risk of HF (from HR 2.40 to 3.30 for
diabetes and CRP, and from HR 2.27 to 3.48 for dia-
betes and fibrinogen) (Table V). Diabetics with pro-
teinuria were at high risk for incident HF, that was
further increased in the presence of elevated fibrinogen
(from HR 3.11 to 4.63 for diabetes and albuminuria
and fibrinogen) but not elevated CRP levels (from HR
3.76 to 3.40 for diabetes with albuminuria and CRP)
(Table VI).
The cumulative hazard for HF by categories of
inflammatory markers is shown in the Figure. Elevated
CRP alone did not significantly increase incident HF
risk; however, elevated fibrinogen was associated with
a significant increase in HF risk (HR, 1.60; 95% CI,
1.39–1.86).
DISCUSSION
This study showed that, in a population with a high
prevalence of obesity, MS, and diabetes, elevated
markers of inflammation predicted increased incident
HF risk. Adjustment for conventional cardiovascular
factors significantly attenuated these associations,
suggesting that inflammatory markers act with other
metabolic risk factors in increasing HF risk. In popula-
tions characterized by the presence of MS, but not
diabetes, elevated CRP and fibrinogen increase inci-
dent HF risk, even after adjustment for conventional
risk factors.
TABLE II. Adjusted HRs of Incident Heart Failure in
Relation to Markers of Inflammation (N=3098)
Incident Heart Failure
HR (95% CI) per SD
Log Increasea,b P Valuea,b
CRP
Age- and sex-adjusted
model
1.25 (1.09–1.44) .001
Multivariate modelc 1.13 (0.97–1.32) .124
Fibrinogen
Age- and sex-adjusted
model
1.60 (1.39–1.86) <.001
Multivariate modelc 1.36 (1.15–1.59) <.001
Odds Ratio (95% CI)
per SD
Log Increasea,d P Valuea,d
MPOd (N=166)
Age- and sex-matched 1.04 (0.78–1.37) .800
Multivariate modelc 1.01 (0.68–1.51) .961
Abbreviations: CI, confidence interval; HR, hazard ratio. aRespective
values for standard deviations (SDs) were fibrinogen=0.226 mg ⁄ dL,
C-reactive protein (CRP)=0.987 mg ⁄ dL, and myeloperoxidase
(MPO)=0.586 pmol ⁄ L. All the biomarkers were log-transformed to
achieve normality. bCox proportional models were used to analyze
the associations between CRP ⁄ fibrinogen and HF. cAdjusted for
age, sex, body mass index, hypertension, low-density lipoprotein
cholesterol, diabetes, smoking, and estimated glomerular filtration
rate. dConditional logistic regression was used to assess the
association between the MPO level and incident heart failure.
TABLE III. Unadjusted and Adjusted HRs for Incident
HF in Relation to Metabolic Syndrome and Markers
of Inflammation (Excluding DM, N=1684)
HR 95% CI P Value
Metabolic syndrome 1.05 0.64–1.74 .838
Metabolic syndrome adjusted for CRP 1.02 0.61–1.72 .927
Metabolic syndrome
adjusted for fibrinogen
0.98 0.58–1.66 .951
Metabolic syndrome adjusted for
conventional risk factorsa
1.14 0.67–1.95 .624
Abbreviations: CI, confidence interval; CRP, C-reactive protein; DM,
diabetes mellitus; HR, hazard ratio. aAdjusted for age, sex, low-den-
sity lipoprotein cholesterol, smoking, and estimated glomerular filtra-
tion rate.
TABLE IV. HRs for Incident HF by Combined Categories of Metabolic Syndrome and Inflammatory Markers
(Excluding DM, N=1684)
MS Inflammatory Markera
CRP Fibrinogen
N Adjusted HR (95% CI)b No. Adjusted HR (95% CI)b
No No 594 1 (referent) 610 1 (referent)
No Yes 131 1.19 (0.44–3.23) 111 0.96 (0.32–2.86)
Yes No 714 0.94 (0.50–1.75) 740 0.86 (0.46–1.60)
Yes Yes 205 2.02 (0.95–4.31) 169 1.75 (0.83–3.72)
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HF, heart failure; HR, hazard ratio; MS, metabolic syndrome. aInflammatory markers: C-
reactive protein (CRP) or fibrinogen >75% percentile (CRP 7 mg ⁄ dL; fibrinogen 398 mg ⁄ dL). bAdjusted for age, sex, low-density lipoprotein cho-
lesterol, smoking, and estimated glomerular filtration rate.
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TABLE V. HRs for Incident HF by Combined Categories of Diabetes Without Albuminuria and Inflammatory
Markers (Excluding Diabetics With Albuminuria, N=2330)
DM Without
Albuminuriaa
Inflammatory
Markerb
CRP Fibrinogen
No. Adjusted HR (95% CI)c No. Adjusted HR (95% CI)c
No No 1278 1 (referent) 1253 1 (referent)
No Yes 362 1.50 (0.85–2.67) 372 1.34 (0.76–2.38)
Yes No 429 2.40 (1.49–3.87) 445 2.27 (1.38–3.72)
Yes Yes 208 3.30 (1.86–5.85) 188 3.48 (2.00–6.05)
Abbreviations: CI, confidence interval; HR, hazard ratio. aDiabetes melitus (DM) without albuminuria (defined as urinary albumin ⁄ creatinine ratio
>30 mg ⁄ g). bInflammatory markers: C-reactive protein (CRP) or fibrinogen >75% percentile (CRP 7 mg ⁄ dL; fibrinogen 398 mg ⁄ dL). cAdjusted for
age, sex, LDL cholesterol, smoking, and estimated glomerular filtration rate.
TABLE VI. HRs for Incident HF by Combined Categories of Diabetes With Albuminuria and Inflammatory Markers
(N=3098)
DM With
Albuminuriaa
Inflammatory
Markerb
CRP Fibrinogen
No.
Adjusted HR
(95% CI)c No.
Adjusted HR
(95% CI)c
No No 1764 1 (referent) 1838 1 (referent)
No Yes 517 1.78 (1.18–2.69) 425 1.86 (1.22–2.83)
Yes No 517 3.76 (2.66–5.32) 421 3.11 (2.11–4.60)
Yes Yes 239 3.40 (2.13–5.43) 332 3.48 (3.16–6.79)
Abbreviations: CI, confidence interval; HR, hazard ratio;. aDefined as urinary albumin ⁄ creatinine ratio >30 mg ⁄ g). bInflammatory markers: C-reactive
protein (CRP) or fibrinogen >75% percentile (CRP 7 mg ⁄ dL; fibrinogen 398 mg ⁄ dL). cAdjusted for age, sex, low-density lipoprotein cholesterol,
smoking, and estimated glomerular filtration rate.
FIGURE. Kaplan–Meier plots of cumulative hazards for incident heart failure (HF) for all Strong Heart Study phase 2 (SHS2) participants by catego-
ries of C-reactive protein (CRP) and fibrinogen (N=3098). The 75th percentile (CRP 7 mg ⁄ dL, fibrinogen 398 mg ⁄ dL) was used as a cutoff to con-
sider an individual ‘‘positive’’ for a given inflammatory marker. Group 1 represents the individuals with CRP and fibrinogen levels <75th percentile;
group 2 with CRP <75th percentile and fibrinogen >75th percentile; group 3 with CRP >75th percentile and fibrinogen <75th percentile; and group
4 had both inflammatory markers >75th percentile. Log-rank test was used for comparison among the groups.
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Systemic inflammation has been associated with HF
in different populations,6,19,20 and inflammatory mark-
ers may be involved directly, or as a marker of under-
lying conditions, in the progression from obesity and
MS to LV dysfunction and HF. In the SHS cohort, ele-
vated CRP concentrations showed a modest associa-
tion with HF that was attenuated after adjustment for
cardiovascular risk factors. These results are in agree-
ment with previous SHS findings that identified high
median CRP concentrations compared with other pop-
ulations, as well as limited value of CRP in predicting
cardiovascular events in diabetic patients.21 The high
prevalence of diabetes in this population has been pro-
posed as a main factor for the observed differences. In
the present study, we also analyzed the role of elevated
CRP in those with MS alone, excluding individuals
with diabetes, and showed a trend towards increased
HF risk in patients with MS who also had elevated
CRP levels. These results are in agreement with other
reports6,19,20 of increased HF risk with elevated CRP
in populations without or with low prevalence of dia-
betes. When we extended the analysis to the diabetic
population, we found that elevated CRP levels were
associated with further increase in incident HF risk in
diabetic patients without albuminuria, but not in dia-
betics with albuminuria. Our results emphasize the
dynamic relationship between subclinical inflamma-
tion, MS, and overt diabetes, and suggest that the role
of inflammation may be more important at intermedi-
ate levels of disease (such as MS and diabetes without
albuminuria) rather than at either extreme.
In contrast to CRP, fibrinogen was more strongly
associated with incident HF in this cohort and this
association persisted after adjusting for conventional
risk factors. In addition to its role in inflammation,
fibrinogen is prothrombotic and has been correlated
with cardiovascular events and HF independently
from known cardiovascular factors and LV hypertro-
phy.6,11 Fibrinogen also can affect microcirculation
by increasing blood viscosity and erythrocyte aggrega-
tion, as well as by altering endothelial reactivity.22
Although fibrinogen concentrations are significantly
correlated with other inflammatory markers, a recent
study from the SHS population showed novel genetic
determinants of fibrinogen concentrations,23 suggest-
ing possible parallel and independent pathways regu-
lating the synthesis and metabolism of acute phase
reactants.
No association was observed between MPO concen-
trations and incident HF in the case-control subset.
This finding is in contrast to recent reports on the role
of MPO in the development and progression of
HF13,24; however, our investigation was limited by the
small number of frozen serum samples in which MPO
was measured. Therefore, the current results may
reflect a lack of statistical power to detect significant
differences in HF events and should not be interpreted
as evidence for the absence of the association between
the MPO and HF.
STRENGTHS AND LIMITATIONS
This study’s strengths include its well-characterized
cohort with high cardiovascular risk, long follow-up,
and carefully adjudicated cardiovascular events includ-
ing HF. We used the ATP III definition of MS and
excluded those with diabetes from the MS analysis to
investigate the role of inflammation and metabolic fac-
tors in the absence of diabetes. This study focused on
a population with a high prevalence of MS and inflam-
mation that has proved to be a model for understand-
ing of diabetic CV disease. The exclusion of diabetic
patients from the MS analysis allowed us to assess HF
risk in individuals with multiple cardiovascular risk
factors and without diabetes, which on its own is a
powerful independent HF predictor.8
This study’s limitations include the small number of
events and the small number of serum samples with
MPO measurements and ⁄or measures of novel inflam-
matory markers, such as interleukin 6 and tumor
necrosis factor a.
CONCLUSIONS
Elevated CRP and fibrinogen predict increased risk of
incident HF in a population with a high prevalence of
obesity, MS, and diabetes. The attenuation of these
associations with adjustment for conventional cardio-
vascular factors suggests that inflammation acts in
concert with other conventional risk factors in increas-
ing HF risk.
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